Latest Dual Listing News

Fonterra Shareholders' Fund has secured conditional approval to delist from the ASX, aiming to consolidate its trading on the NZX by late February 2025. This move is expected to streamline operations and reduce costs for unitholders.

Mesoblast has raised A$260 million through a global private placement to fund the US commercial launch of its FDA-approved cell therapy Ryoncil® and accelerate clinical development in chronic low back pain.